A number of randomized, double-blind, placebo-controlled studies in patients with T2DM have evaluated the efficacy of dapagliflozin as adjunctive therapy with metformin [28, 47, 50–57] and insulin [58–61]. Here, INS is linked to type 2 diabetes mellitus.